Search Results
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Thomas Edouard in
Google Scholar
PubMed
Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy
Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Martin Zenker in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Introduction
Mutations in PTPN11 are associated with Noonan syndrome (NS). Although the effectiveness of growth hormone therapy (GHT) in treating short stature due to NS has been previously demonstrated, the effect of PTPN11 mutation status on the long-term outcomes of GHT remains to be elucidated.
Methods
This analysis included pooled data from the observational American Norditropin Studies: Web-Enabled Research Program (NCT01009905) and the randomized, double-blinded GHLIQUID-4020 clinical trial (NCT01927861). Pediatric patients with clinically diagnosed NS and confirmed PTPN11mutation status were eligible for inclusion. The effectiveness analysis included patients who were GHT-naïve and pre-pubertal at GHT start. Growth outcomes and safety were assessed over 4 years of GHT (Norditropin®, Novo Nordisk A/S).
Results
A total of 69 patients were included in the effectiveness analysis (71% PTPN11 positive). The proportion of females was 32.7 and 30.0% in PTPN11-positive and negative patients, respectively, and mean age at GHT start was 6.4 years in both groups. Using general population reference data, after 4 years of GHT, the mean (s.d.) height SD score (HSDS) was −1.9 (1.1) and −1.7 (0.8) for PTPN11-positive and PTPN11-negative patients, respectively, with no statistical difference observed between groups. The mean (s.d.) change in HSDS at 4 years was +1.3 (0.8) in PTPN11-positive patients and +1.5 (0.7) in PTPN11-negative patients (no significant differences between groups). Safety findings were consistent with previous analyses.
Conclusions
GHT resulted in improved growth outcomes over 4 years in GHT-naïve, pre-pubertal NS patients, irrespective of PTPN11 mutation status.
Disciplina de Endocrinologia, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, São Paulo, Brazil
Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular LIM/42, Disciplina de Endocrinologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Renata C Scalco in
Google Scholar
PubMed
Search for other papers by Ericka B Trarbach in
Google Scholar
PubMed
Search for other papers by Edoarda V A Albuquerque in
Google Scholar
PubMed
Search for other papers by Thais K Homma in
Google Scholar
PubMed
Search for other papers by Thais H Inoue-Lima in
Google Scholar
PubMed
Search for other papers by Mirian Y Nishi in
Google Scholar
PubMed
Search for other papers by Berenice B Mendonca in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Most patients with Turner syndrome (TS) need hormone replacement therapy because of hypergonadotropic hypogonadism; individual outcomes, however, are highly variable. Our objective was to assess the influence of five estrogen receptor 1 gene (ESR1) polymorphisms (rs543650, rs1038304, rs2046210, rs2234693 and rs9340799) on adult height, breast development, uterine volume and bone mineral density (BMD). We studied 91 TS patients from a tertiary hospital using adult estrogen dose. In our group, ESR1 rs2234693 was associated with femoral neck and total hip BMD, and it accounted for around 10% of BMD variability in both sites (P < 0.01). Patients homozygous for C allele in this polymorphism had significantly lower femoral neck BMD (0.699 ± 0.065 g/cm2 vs 0.822 ± 0.113 g/cm2, P = 0.008) and total hip BMD (0.777 ± 0.118 g/cm2 vs 0.903 ± 0.098 g/cm2, P = 0.009) than patients homozygous for T allele. The other four ESR1 polymorphisms were not able to predict any of the above estrogen therapy outcomes in an isolated manner. Patients homozygous for the haplotype GCG formed by polymorphisms rs543650, rs2234693 and rs9340799 had an even more significantly lower femoral neck BMD (0.666 ± 0.049 vs 0.820 ± 0.105 g/cm2, P = 0.0047) and total hip BMD (0.752 ± 0.093 vs 0.908 ± 0.097 g/cm2, P = 0.0029) than patients homozygous for haplotypes with a T allele in rs2234693. In conclusion, homozygosity for C allele in ESR1 rs2234693 and/or for GCG haplotype appears to be associated with lower femoral neck and total hip BMD. We believe that the identification of polymorphisms related to estrogen outcomes may contribute to individualization of treatment in TS.
Search for other papers by Marilena Nakaguma in
Google Scholar
PubMed
Search for other papers by Fernanda A Correa in
Google Scholar
PubMed
Search for other papers by Lucas S Santana in
Google Scholar
PubMed
Search for other papers by Anna F F Benedetti in
Google Scholar
PubMed
Search for other papers by Ricardo V Perez in
Google Scholar
PubMed
Search for other papers by Martha K P Huayllas in
Google Scholar
PubMed
Search for other papers by Mirta B Miras in
Google Scholar
PubMed
Search for other papers by Mariana F A Funari in
Google Scholar
PubMed
Search for other papers by Antonio M Lerario in
Google Scholar
PubMed
Search for other papers by Berenice B Mendonca in
Google Scholar
PubMed
Search for other papers by Luciani R S Carvalho in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Ivo J P Arnhold in
Google Scholar
PubMed
Aim
Congenital hypopituitarism has an incidence of 1:3500–10,000 births and is defined by the impaired production of pituitary hormones. Early diagnosis has an impact on management and genetic counselling. The clinical and genetic heterogeneity of hypopituitarism poses difficulties to select the order of genes to analyse. The objective of our study is to screen hypopituitarism genes (candidate and previously related genes) simultaneously using a target gene panel in patients with congenital hypopituitarism.
Methods
Screening of 117 subjects with congenital hypopituitarism for pathogenic variants in 26 genes associated with congenital hypopituitarism by massively parallel sequencing using a customized target gene panel.
Results
We found three novel pathogenic variants in OTX2 c.295C>T:p.Gln99*, GLI2 c.1681G>T:p.Glu561* and GHRHR c.820_821insC:p.Asp274Alafs*113, and the previously reported variants in GHRHR c.57+1G>A and PROP1 [c.301_302delAG];[c.109+1G>A].
Conclusions
Our results indicate that a custom-designed panel is an efficient method to screen simultaneously variants of biological and clinical relevance for congenital GH deficiency. A genetic diagnosis was possible in 5 out of 117 (4%) patients of our cohort. We identified three novel pathogenic variants in GHRHR, OTX2 and GLI2 expanding the spectrum of variants associated with congenital hypopituitarism.
Search for other papers by Fernanda A Correa in
Google Scholar
PubMed
Search for other papers by Ericka B Trarbach in
Google Scholar
PubMed
Search for other papers by Cintia Tusset in
Google Scholar
PubMed
Search for other papers by Ana Claudia Latronico in
Google Scholar
PubMed
Search for other papers by Luciana R Montenegro in
Google Scholar
PubMed
Search for other papers by Luciani R Carvalho in
Google Scholar
PubMed
Search for other papers by Marcela M Franca in
Google Scholar
PubMed
Search for other papers by Aline P Otto in
Google Scholar
PubMed
Search for other papers by Everlayny F Costalonga in
Google Scholar
PubMed
Search for other papers by Vinicius N Brito in
Google Scholar
PubMed
Search for other papers by Ana Paula Abreu in
Google Scholar
PubMed
Search for other papers by Mirian Y Nishi in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Ivo J P Arnhold in
Google Scholar
PubMed
Search for other papers by Yisrael Sidis in
Google Scholar
PubMed
Search for other papers by Nelly Pitteloud in
Google Scholar
PubMed
Search for other papers by Berenice B Mendonca in
Google Scholar
PubMed
The genetic aetiology of congenital hypopituitarism (CH) is not entirely elucidated. FGFR1 and PROKR2 loss-of-function mutations are classically involved in hypogonadotrophic hypogonadism (HH), however, due to the clinical and genetic overlap of HH and CH; these genes may also be involved in the pathogenesis of CH. Using a candidate gene approach, we screened 156 Brazilian patients with combined pituitary hormone deficiencies (CPHD) for loss-of-function mutations in FGFR1 and PROKR2. We identified three FGFR1 variants (p.Arg448Trp, p.Ser107Leu and p.Pro772Ser) in four unrelated patients (two males) and two PROKR2 variants (p.Arg85Cys and p.Arg248Glu) in two unrelated female patients. Five of the six patients harbouring the variants had a first-degree relative that was an unaffected carrier of it. Results of functional studies indicated that the new FGFR1 variant p.Arg448Trp is a loss-of-function variant, while p.Ser107Leu and p.Pro772Ser present signalling activity similar to the wild-type form. Regarding PROKR2 variants, results from previous functional studies indicated that p.Arg85Cys moderately compromises receptor signalling through both MAPK and Ca2 + pathways while p.Arg248Glu decreases calcium mobilization but has normal MAPK activity. The presence of loss-of-function variants of FGFR1 and PROKR2 in our patients with CPHD is indicative of an adjuvant and/or modifier effect of these rare variants on the phenotype. The presence of the same variants in unaffected relatives implies that they cannot solely cause the phenotype. Other associated genetic and/or environmental modifiers may play a role in the aetiology of this condition.
Search for other papers by Nathalia Liberatoscioli Menezes Andrade in
Google Scholar
PubMed
Search for other papers by Mariana Ferreira de Assis Funari in
Google Scholar
PubMed
Search for other papers by Alexsandra Christianne Malaquias in
Google Scholar
PubMed
Search for other papers by Paulo Ferrez Collett-Solberg in
Google Scholar
PubMed
Search for other papers by Nathalia L R A Gomes in
Google Scholar
PubMed
Departamento de Medicina, Faculdade de Ciencias Medicas da Santa Casa de Sao Paulo, Sao Paulo, Brasil
Search for other papers by Renata Scalco in
Google Scholar
PubMed
Search for other papers by Naiara Castelo Branco Dantas in
Google Scholar
PubMed
Search for other papers by Raissa C Rezende in
Google Scholar
PubMed
Search for other papers by Angelica M F P Tiburcio in
Google Scholar
PubMed
Search for other papers by Micheline A R Souza in
Google Scholar
PubMed
Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular (LIM42), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo (USP), Sao Paulo, Brasil
Search for other papers by Bruna L Freire in
Google Scholar
PubMed
Search for other papers by Ana C V Krepischi in
Google Scholar
PubMed
Search for other papers by Carlos Alberto Longui in
Google Scholar
PubMed
Search for other papers by Antonio Marcondes Lerario in
Google Scholar
PubMed
Search for other papers by Ivo J P Arnhold in
Google Scholar
PubMed
Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular (LIM42), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo (USP), Sao Paulo, Brasil
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular (LIM42), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo (USP), Sao Paulo, Brasil
Search for other papers by Gabriela Andrade Vasques in
Google Scholar
PubMed
Objective
Most children with short stature remain without an etiologic diagnosis after extensive clinical and laboratory evaluation and are classified as idiopathic short stature (ISS). This study aimed to determine the diagnostic yield of a multigene analysis in children classified as ISS.
Design and methods
We selected 102 children with ISS and performed the genetic analysis as part of the initial investigation. We developed customized targeted panel sequencing, including all genes already implicated in the isolated short-stature phenotype. Rare and deleterious single nucleotide or copy number variants were assessed by bioinformatic tools.
Results
We identified 20 heterozygous pathogenic (P) or likely pathogenic (LP) genetic variants in 17 of 102 patients (diagnostic yield = 16.7%). Three patients had more than one P/LP genetic alteration. Most of the findings were in genes associated with the growth plate differentiation: IHH (n = 4), SHOX (n = 3), FGFR3 (n = 2), NPR2 (n = 2), ACAN (n = 2), and COL2A1 (n = 1) or involved in the RAS/MAPK pathway: NF1 (n = 2), PTPN11 (n = 1), CBL (n = 1), and BRAF (n = 1). None of these patients had clinical findings to guide a candidate gene approach. The diagnostic yield was higher among children with severe short stature (35% vs 12.2% for height SDS ≤ or > −3; P = 0.034). The genetic diagnosis had an impact on clinical management for four children.
Conclusion
A multigene sequencing approach can determine the genetic etiology of short stature in up to one in six children with ISS, removing the term idiopathic from their clinical classification.
Search for other papers by Nathalia G B P Ferreira in
Google Scholar
PubMed
Search for other papers by Joao L O Madeira in
Google Scholar
PubMed
Search for other papers by Peter Gergics in
Google Scholar
PubMed
Search for other papers by Renata Kertsz in
Google Scholar
PubMed
Search for other papers by Juliana M Marques in
Google Scholar
PubMed
Search for other papers by Nicholas S S Trigueiro in
Google Scholar
PubMed
Search for other papers by Anna Flavia Figueredo Benedetti in
Google Scholar
PubMed
Search for other papers by Bruna V Azevedo in
Google Scholar
PubMed
Universidade de São Paulo, Zebrafish Facility, São Paulo, São Paulo, Brazil
Search for other papers by Bianca H V Fernandes in
Google Scholar
PubMed
Search for other papers by Debora D Bissegatto in
Google Scholar
PubMed
Search for other papers by Isabela P Biscotto in
Google Scholar
PubMed
Search for other papers by Qing Fang in
Google Scholar
PubMed
Search for other papers by Qianyi Ma in
Google Scholar
PubMed
Search for other papers by Asye B Ozel in
Google Scholar
PubMed
Search for other papers by Jun Li in
Google Scholar
PubMed
Search for other papers by Sally A Camper in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Berenice B Mendonça in
Google Scholar
PubMed
Search for other papers by Ivo J P Arnhold in
Google Scholar
PubMed
Search for other papers by Luciani R Carvalho in
Google Scholar
PubMed
Context
Congenital hypopituitarism is a genetically heterogeneous condition. Whole exome sequencing (WES) is a promising approach for molecular diagnosis of patients with this condition.
Objectives
The aim of this study is to conduct WES in a patient with congenital hypopituitarism born to consanguineous parents, CDH2 screening in a cohort of patients with congenital hypopituitarism, and functional testing of a novel CDH2 variant.
Design
Genomic DNA from a proband and her consanguineous parents was analyzed by WES. Copy number variants were evaluated. The genetic variants were filtered for population frequency (ExAC, 1000 genomes, gnomAD, and ABraOM), in silico prediction of pathogenicity, and gene expression in the pituitary and/or hypothalamus. Genomic DNA from 145 patients was screened for CDH2 by Sanger sequencing.
Results
One female patient with deficiencies in growth hormone, thyroid-stimulating hormone, adrenocorticotropic hormone, luteinizing hormone, and follicle-stimulating hormone and ectopic posterior pituitary gland contained a rare homozygous c.865G>A (p.Val289Ile) variant in CDH2. To determine whether the p.Val289Ile variant in CDH2 affects cell adhesion properties, we stably transfected L1 fibroblast lines, labeled the cells with lipophilic dyes, and quantified aggregation. Large aggregates formed in cells expressing wildtype CDH2, but aggregation was impaired in cells transfected with variant CDH2 or non-transfected.
Conclusion
A homozygous CDH2 allelic variant was found in one hypopituitarism patient, and the variant impaired cell aggregation function in vitro. No disease-causing variants were found in 145 other patients screened for CDH2 variants. Thus, CDH2 is a candidate gene for hypopituitarism that needs to be tested in different populations.
Significance statement
A female patient with hypopituitarism was born from consanguineous parents and had a homozygous, likely pathogenic, CDH2 variant that impairs cell aggregation in vitro. No other likely pathogenic variants in CDH2 were identified in 145 hypopituitarism patients.
Search for other papers by Rui M B Maciel in
Google Scholar
PubMed
Search for other papers by Cleber P Camacho in
Google Scholar
PubMed
Search for other papers by Lígia V M Assumpção in
Google Scholar
PubMed
Search for other papers by Natassia E Bufalo in
Google Scholar
PubMed
Search for other papers by André L Carvalho in
Google Scholar
PubMed
Search for other papers by Gisah A de Carvalho in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Luciana A Castroneves in
Google Scholar
PubMed
Search for other papers by Francisco M de Castro Jr in
Google Scholar
PubMed
Search for other papers by Lucieli Ceolin in
Google Scholar
PubMed
Search for other papers by Janete M Cerutti in
Google Scholar
PubMed
Search for other papers by Rossana Corbo in
Google Scholar
PubMed
Search for other papers by Tânia M B L Ferraz in
Google Scholar
PubMed
Search for other papers by Carla V Ferreira in
Google Scholar
PubMed
Hospital Santa Rita de Cássia, Vitória, Espírito Santo, Brazil
Search for other papers by M Inez C França in
Google Scholar
PubMed
Search for other papers by Henrique C R Galvão in
Google Scholar
PubMed
Search for other papers by Fausto Germano-Neto in
Google Scholar
PubMed
Search for other papers by Hans Graf in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Ilda S Kunii in
Google Scholar
PubMed
Search for other papers by Márcio W Lauria in
Google Scholar
PubMed
Search for other papers by Vera L G Leal in
Google Scholar
PubMed
Search for other papers by Susan C Lindsey in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Delmar M Lourenço Jr in
Google Scholar
PubMed
Search for other papers by Léa M Z Maciel in
Google Scholar
PubMed
Search for other papers by Patrícia K R Magalhães in
Google Scholar
PubMed
Search for other papers by João R M Martins in
Google Scholar
PubMed
Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil
Universidade de Fortaleza, Fortaleza, Ceará, Brazil
Search for other papers by M Cecília Martins-Costa in
Google Scholar
PubMed
Search for other papers by Gláucia M F S Mazeto in
Google Scholar
PubMed
Search for other papers by Anelise I Impellizzeri in
Google Scholar
PubMed
Search for other papers by Célia R Nogueira in
Google Scholar
PubMed
Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, São Paulo, Brazil
Search for other papers by Edenir I Palmero in
Google Scholar
PubMed
Search for other papers by Cencita H C N Pessoa in
Google Scholar
PubMed
Search for other papers by Bibiana Prada in
Google Scholar
PubMed
Search for other papers by Débora R Siqueira in
Google Scholar
PubMed
Escola Fiocruz de Governo, Fundação Oswaldo Cruz and Ministério da Saúde, Brasília, Distrito Federal, Brazil
Search for other papers by Maria Sharmila A Sousa in
Google Scholar
PubMed
Vall d’Hebron Institute of Oncology (VHIO), CIBERONC, Barcelona, Spain
Search for other papers by Rodrigo A Toledo in
Google Scholar
PubMed
Search for other papers by Flávia O F Valente in
Google Scholar
PubMed
Search for other papers by Fernanda Vaisman in
Google Scholar
PubMed
Search for other papers by Laura S Ward in
Google Scholar
PubMed
Search for other papers by Shana S Weber in
Google Scholar
PubMed
Search for other papers by Rita V Weiss in
Google Scholar
PubMed
Search for other papers by Ji H Yang in
Google Scholar
PubMed
Search for other papers by Magnus R Dias-da-Silva in
Google Scholar
PubMed
Instituto do Câncer do Estado de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Ana O Hoff in
Google Scholar
PubMed
Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil
Search for other papers by Sergio P A Toledo in
Google Scholar
PubMed
Search for other papers by Ana L Maia in
Google Scholar
PubMed
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant genetic disease caused by RET gene germline mutations that is characterized by medullary thyroid carcinoma (MTC) associated with other endocrine tumors. Several reports have demonstrated that the RET mutation profile may vary according to the geographical area. In this study, we collected clinical and molecular data from 554 patients with surgically confirmed MTC from 176 families with MEN2 in 18 different Brazilian centers to compare the type and prevalence of RET mutations with those from other countries. The most frequent mutations, classified by the number of families affected, occur in codon 634, exon 11 (76 families), followed by codon 918, exon 16 (34 families: 26 with M918T and 8 with M918V) and codon 804, exon 14 (22 families: 15 with V804M and 7 with V804L). When compared with other major published series from Europe, there are several similarities and some differences. While the mutations in codons C618, C620, C630, E768 and S891 present a similar prevalence, some mutations have a lower prevalence in Brazil, and others are found mainly in Brazil (G533C and M918V). These results reflect the singular proportion of European, Amerindian and African ancestries in the Brazilian mosaic genome.
